Rinvoq ER 45 MG tablet UU 28S
Ended Awarded Last action
- Contract number
- SPE2DR26FN0K7
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $54,795
Award facts
- Contract value 100% obligated
- $54,794.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $54,794.86 to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 16, 2026, for the supply of RINVOQ ER 45 MG tablets in quantities of 28 units. This firm fixed-price delivery order, which carries an ultimate completion date of January 20, 2026, was competitively awarded with no set-aside designation. The award is being fulfilled from the place of performance located in Conshohocken, Pennsylvania, where the contractor maintains its corporate office. This delivery order falls under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government, supporting the Defense Health Agency and military healthcare systems.
This award is a task order under AmerisourceBergen's parent company Cencora, Inc.'s Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2031), which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. RINVOQ (upadacitinib) is a JAK inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the breadth of specialty medications supplied through this strategic contract vehicle. AmerisourceBergen's established position as a prime pharmaceutical vendor demonstrates its critical role in ensuring consistent delivery of essential medications to federal healthcare systems worldwide.
Quick answers
Who was awarded contract SPE2DR26FN0K7?
SPE2DR26FN0K7 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26FN0K7 worth?
The government has obligated $54,795 on SPE2DR26FN0K7.
Is contract SPE2DR26FN0K7 an order under another contract?
Yes. SPE2DR26FN0K7 is a delivery order under SPE2DR25D2211, an indefinite delivery contract.
Was contract SPE2DR26FN0K7 competed?
The extent of competition for SPE2DR26FN0K7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award